(Total Views: 530)
Posted On: 06/20/2021 7:28:10 PM
Post# of 145909
![](/m/assets/46931549/no_avatar_available_thumb.jpg)
Re: nothingspecial #94062
I think in the upcoming longhaulers trial they should be a little picky. Those with few symptoms will not differentiate leronlimab as widely from placebo as those that have many. Also inclusion/exclusion should be based partially on the endpoints. For instance if one of the endpoints is a walking test inclusion requires pulmonary problems. This should set the trial up for best possible results.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)